Prognostic Significance of Stromelysin-3 and Tissue Inhibitor of Matrix Metalloproteinase-2 in Esophageal Cancer

Objective: Stromelysins (matrix metalloproteinases: MMP-10 or ST-2 and MMP-11 or ST-3) and tissue inhibitors of matrix metalloproteinases (TIMP-1 and 2) have been shown to be associated with human tumor progression, invasion and metastasis. The aim of the present study was to determine the prognostic significance of these proteins in esophageal squamous cell carcinoma (ESCC). Methods: Immunohistochemical analysis was carried out in 65 surgically resected ESCCs and 49 distant histologically normal esophageal tissues and 16 cases of dysplasias. Statistical analyses were performed to determine the associations between the protein expression and clinicopathological parameters and survival of esophageal cancer patients. Results: Expression of ST-2, ST-3, TIMP-1 and TIMP-2 was observed in 43/65 (66%), 51/65 (78%), 43/65 (66%) and 47/65 (72%) ESCC cases, respectively. Univariate analysis showed that TIMP-2 expression was associated with tumor site (OR = 2.63, p = 0.017). TIMP-1+/TIMP-2+ phenotype was inversely correlated with nodal invasiveness of the tumor (OR = 0.4, p = 0.04). Interestingly, p53 expression was associated with increased levels of ST-3 (OR = 0.11, p = 0.02) and TIMP-1 (OR = 3.2, p = 0.007) suggesting possible involvement of p53 in the regulation of these proteins. An increased expression of ST-2, ST-3, TIMP-1 and TIMP-2 was observed in 11/16 (69%), 7/17 (44%), 11/16 (69%) and 8/16 (50%) dysplasias also suggesting that these alterations are early events in esophageal tumorigenesis. All the ESCC patients were followed up postesophagectomy for a maximum period of 59 months (mean disease-free survival = 12 months). Kaplan-Meier survival analysis showed that patients with ST-3-positive and TIMP-2-negative carcinoma had a significantly shorter disease-free survival (median disease-free survival time of 4 months) as compared to patients in the other groups (median disease-free survival time of 20 months; p = 0.0016). To our knowledge this is the first report showing that ST-3+/TIMP-2– phenotype remained of significant predictive value for disease-free survival (p = 0.0007) in multivariate analysis including a conventional clinicopathological factor, tumor stage (p = 0.051). Conclusion: Our results suggest that ST-3+/TIMP-2– phenotype is an adverse prognosticator in esophageal cancer patients.

[1]  R. Ralhan,et al.  Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. , 2002, Cancer detection and prevention.

[2]  W. Stetler-Stevenson,et al.  Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. , 2001, The American journal of pathology.

[3]  C. Sautès-Fridman,et al.  High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. , 2001, Cancer research.

[4]  I. Goldberg,et al.  Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. , 2001, Cancer research.

[5]  W. Stetler-Stevenson,et al.  Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Suppresses TKR-Growth Factor Signaling Independent of Metalloproteinase Inhibition* , 2001, The Journal of Biological Chemistry.

[6]  H. Höfler,et al.  Stromelysin-3 expression in invasive ovarian carcinomas and tumours of low malignant potential , 2000, Virchows Archiv.

[7]  B. Bodey,et al.  Immunocytochemical detection of MMP-3 and -10 expression in hepatocellular carcinomas. , 2000, Anticancer research.

[8]  C. López-Otín,et al.  Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. , 2000, Cancer research.

[9]  S. Curran,et al.  Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. , 2000, European journal of cancer.

[10]  J. Wyke.  Overview--burgeoning promise in metastasis research. , 2000, European journal of cancer.

[11]  R. Altman,et al.  Wild Type and Mutant p53 Differentially Regulate the Gene Expression of Human Collagenase-3 (hMMP-13)* , 2000, The Journal of Biological Chemistry.

[12]  J. Foidart,et al.  Demonstration in vivo that stromelysin-3 functions through its proteolytic activity , 2000, Oncogene.

[13]  R. E. Luna,et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. , 2000, Human pathology.

[14]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[15]  G. Li,et al.  Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. , 1999, Cancer research.

[16]  D. Pinkel,et al.  The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis , 1999, Cell.

[17]  P. Henriet,et al.  Tissue inhibitors of matrix metalloproteinases in cancer. , 1999, Annals of the New York Academy of Sciences.

[18]  H. Harada,et al.  Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology , 1999, British Journal of Cancer.

[19]  P. Henriet,et al.  INHIBITION OF MATRIX METALLOPROTEINASES THERAPEUTIC APPLICATIONS , 1999 .

[20]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. , 1999, The Journal of clinical investigation.

[21]  Y. Sun,et al.  p53 Down-regulates Human Matrix Metalloproteinase-1 (Collagenase-1) Gene Expression* , 1999, The Journal of Biological Chemistry.

[22]  C. Luparello,et al.  Tissue inhibitor of metalloprotease (TIMP)‐1 and proliferative behaviour of clonal breast cancer cells , 1999, Breast Cancer Research and Treatment.

[23]  M. Duffy,et al.  High levels of tissue inhibitor of metalloproteinase‐1 predict poor outcome in patients with breast cancer , 1999, International journal of cancer.

[24]  M. Stoppelli,et al.  Proteases and cancer invasion: from belief to certainty. AACR meeting on proteases and protease inhibitors in cancer, Nyborg, Denmark, 14-18 June 1998. , 1999, Biochimica et biophysica acta.

[25]  W. Stetler-Stevenson,et al.  In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. , 1998, The Journal of clinical investigation.

[26]  L. Matrisian,et al.  Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis , 1998, International journal of cancer.

[27]  B. Nordlinger,et al.  Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  J. Foidart,et al.  In Vivo Evidence That the Stromelysin-3 Metalloproteinase Contributes in a Paracrine Manner to Epithelial Cell Malignancy , 1998, The Journal of cell biology.

[29]  R. Poulsom,et al.  Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. , 1998, The American journal of pathology.

[30]  D. Gomez,et al.  Mammary carcinoma cells over‐expressing tissue inhibitor of metalloproteinases‐1show vascular endothelial growth factor expression , 1998 .

[31]  Y. Sun,et al.  Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter , 1997, Molecular and cellular biology.

[32]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[33]  D. Gomez,et al.  Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.

[34]  C. Pond,et al.  Adaptations of Maternal Adipose Tissue to Lactation , 1997, Journal of Mammary Gland Biology and Neoplasia.

[35]  A. Noël,et al.  Stromelysin-3: a paradigm for stroma-derived factors implicated in carcinoma progression. , 1997, Critical reviews in oncology/hematology.

[36]  P. Basset,et al.  Expression of Matrix Metalloproteinases during Rat Skin Wound Healing: Evidence that Membrane Type-1 Matrix Metalloproteinase Is a Stromal Activator of Pro-Gelatinase A , 1997, The Journal of cell biology.

[37]  M. Duffy,et al.  High levels of stromelysin‐3 correlate with poor prognosis in patients with breast carcinoma , 1996, International journal of cancer.

[38]  H. Shimada,et al.  Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. , 1996, Cancer research.

[39]  A. Noël,et al.  Stromelysin-3 in the biology of the normal and neoplastic mammary gland , 1996, Journal of Mammary Gland Biology and Neoplasia.

[40]  M. Shipp,et al.  Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. , 1995, Cancer research.

[41]  E. Miyagi,et al.  Characterization of Matrix‐degrading Proteinases and Their Inhibitors Secreted by Human Gynecological Carcinoma Cells , 1995, Japanese journal of cancer research : Gann.

[42]  Stephen J. Weiss,et al.  Furin-dependent intracellular activation of the human stromelysin-3 zymogen , 1995, Nature.

[43]  E. Kohn,et al.  Molecular insights into cancer invasion: strategies for prevention and intervention. , 1995, Cancer research.

[44]  P. Chambon,et al.  Developmental expression of mouse stromelysin-3 mRNA. , 1995, Development.

[45]  P. Chambon,et al.  Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin‐3 and BM‐40/SPARC genes , 1995, International journal of cancer.

[46]  C. Soria,et al.  The effect of platelets on invasiveness and protease production of human mammary tumor cells , 1995, International journal of cancer.

[47]  P. Chambon,et al.  The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. , 1993, The Journal of biological chemistry.

[48]  H. Yoshida,et al.  Role of plasminogen activators, metalloproteinases and the tissue inhibitor of metalloproteinase‐1 in the metastatic process of human salivary‐gland adenocarcinoma cells , 1993, International journal of cancer.

[49]  P. Basset,et al.  The breast cancer-associated stromelysin-3 gene is expressed during mouse mammary gland apoptosis , 1992, The Journal of cell biology.

[50]  K. Iwata,et al.  Growth‐promoting activity of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) for a wide range of cells A possible new growth factor in serum , 1992, FEBS letters.

[51]  M. Cockett,et al.  Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). , 1991, The Biochemical journal.

[52]  J. Abecassis,et al.  Expression of collagenase‐related metalloproteinase genes in human lung or head and neck tumours , 1991, International journal of cancer.

[53]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[54]  R. Ralhan,et al.  Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. , 2002, European journal of cancer.

[55]  Masashi Kobayashi,et al.  Ionizing radiation enhances matrix metalloproteinase-2 production in human lung epithelial cells. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[56]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[57]  D. Gomez,et al.  Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. , 1998, International journal of cancer.

[58]  L. Devy,et al.  Emerging roles for proteinases in cancer. , 1997, Invasion & metastasis.

[59]  Y. DeClerck,et al.  Protease inhibitors: role and potential therapeutic use in human cancer. , 1994 .

[60]  H. Sato,et al.  Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. , 1992, Oncogene.

[61]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[62]  O. Beahrs.  The American Joint Committee on Cancer. , 1984, Bulletin of the American College of Surgeons.